Schizophrenia remains a major health burden, highlighting the need for new treatment
approaches. We consider the potential for targeting the trace amine (TA) system. We first …

Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target
for neuropsychiatric disorders due to its ability to modulate monoaminergic and …

The discovery in 2001 of a G protein-coupled receptor family, subsequently termed trace
amine-associated receptors (TAAR), triggered a resurgence of interest in so-called trace …

Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-
HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough …

TAAR1 is widely expressed across the mammalian brain, particularly in limbic and
monoaminergic areas, allegedly involved in mood, attention, memory, fear, and addiction …

Biogenic amines are a collection of endogenous molecules that play pivotal roles as
neurotransmitters and hormones. In addition to the “classical” biogenic amines resulting …

Compulsive eating behavior is a transdiagnostic construct that is characteristic of medical
and psychiatric conditions such as forms of obesity and eating disorders. Although feeding …

Alterations in dopamine neurotransmission are generally associated with diseases such as
attention-deficit/hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) …

Trace amines, a group of amines expressed at the nanomolar level in the mammalian brain,
can modulate monoamine transmission. The discovery of and the functional research on the …

Abstract d-lysergic diethylamide (LSD) is a hallucinogenic drug that interacts with the
serotonin (5-HT) system binding to 5-HT 1 and 5-HT 2 receptors. Little is known about its …